Substituted indole compounds having NOS inhibitory activity

Details Substituted indole compounds having NOS inhibitory activity Substituted indole compounds having NOS inhibitory activity

2008-05-20

2008-05-20

Powers, Fiona T (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Unsubstituted hydrocarbyl chain between the ring and the -c-...

C544S143000, C546S112000, C546S135000, C546S201000, C546S277400, C548S312100, C548S466000, C548S467000, C548S503000, C514S217080, C514S235200, C514S299000, C514S305000, C514S323000, C514S339000, C514S414000

Reexamination Certificate

active

07375219

ABSTRACT:
The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia.

REFERENCES:
patent: 4324790 (1982-04-01), Guillaume et al.
patent: 4839377 (1989-06-01), Bays et al.
patent: 5070102 (1991-12-01), Traber et al.
patent: 5200410 (1993-04-01), Traber et al.
patent: 5708008 (1998-01-01), Audia et al.
patent: 5874427 (1999-02-01), Filla et al.
patent: 5998438 (1999-12-01), Slassi et al.
patent: 7141595 (2006-11-01), Ramnauth et al.
patent: 2003/0064991 (2003-04-01), Harriman et al.
patent: 2004/0142935 (2004-07-01), Schiemann et al.
patent: 2004/0259891 (2004-12-01), Agarwal et al.
patent: 2005/0032791 (2005-02-01), Merc-Vidal et al.
patent: 2005/0075348 (2005-04-01), Harriman et al.
patent: 2007/0105943 (2007-05-01), Nakamoto et al.
patent: 2007/0254940 (2007-11-01), Maddaford et al.
patent: 0262873 (1988-04-01), None
patent: 0574618 (1993-12-01), None
patent: 1 571 142 (2005-09-01), None
patent: 6212151 (1994-08-01), None
patent: 2000280626 (2000-10-01), None
patent: 2005129430 (2005-05-01), None
patent: WO9747302 (1997-12-01), None
patent: WO9811895 (1998-03-01), None
patent: WO0000487 (2000-01-01), None
patent: WO0017198 (2000-03-01), None
patent: WO 01/12187 (2001-02-01), None
patent: WO-01/32619 (2001-05-01), None
patent: WO 02/16318 (2002-02-01), None
patent: WO 03/051275 (2003-06-01), None
patent: WO 2004/014885 (2004-02-01), None
patent: WO2005013974 (2005-02-01), None
patent: WO2005024416 (2005-03-01), None
patent: WO2005090282 (2005-09-01), None
Johnson et al., Chemical Abstracts, 128:192544, 1998.
Johnson et al., Chemical Abstracts, 128;257330, 1998.
Kitazawa et al., Chemical Abstracts, 129:302552, 1998.
Anderson et al, “Palladium-Catalyzed Amination of Aryl Nonaflates,”J. Org. Chem., 68: 9563-9573 (2003).
Antilla et al., “Copper-Catalyzed Coupling of Arylboronic Acids and Amines,”Org. Lett., 3: 2077-2079 (2001).
Baati et al., “An Improved Method for the Preparation of Amidines via Thiophenylimidic Esters,”Synthesis, 927-929 (1999).
Blair et al., “Effect of Ring Fluorination on the Pharmacology of Hallucinogenic Tryptamines,”J. Med. Chem., 43: 4701-4710 (2000).
Coe et al., “Convenient preparation of N-substituted indoles by modified Leimgruber-Batcho indole synthesis,”Tetrahedron Lett., 37: 6045-6048 (1996).
Cooper et al., “2-Aryl Indole NK1 Receptor Antagonists: Pptimisation of Indole Substitution,”Bioorg. Med. Chem. Lett., 11: 1233-1236 (2001).
Heaney et al., “1-Benzylindole,”Org. Synth., 54: 58 (1974) [http://www.orgsyn.org/orgsyn/prep.asp?prep=cv6p0104].
Huang et al., “New Ammonia Equivalents for the Pd-Catalyzed Amination of Aryl Halides,”Org. Lett., 3: 3417-3419 (2001).
Macor et al., “5-[(3-Nitropyrid-2-yl)amino]indoles: Novel Serotonin Agonists with Selectivity for the 5-HT1D Receptor, Variation of the C3 Substituent on the Indole Template Leads to Increased 5-HT1D Receptor Selectivity,”J. Med. Chem., 37: 2509-2512 (1994).
Macor et al., “Use of 2,5-Dimethylpyrrole as an Amino-Protecting Group in an Efficient Synthesis of 5-Amino-3-[(N-methyl-pyrrolidin-2(R)-yl)methyl]indole,”J. Org. Chem., 59: 7496-7498 (1994).
Perregaard et al., “Selective, centrally acting serotonin 5-HT2 antagonists. 1. 2- and 6-Substituted 1-phenyl-3-(4-piperidinyl)-1H-indoles”J. Med. Chem., 35: 4813-4822 (1992).
Rowley et al., “3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as High Affinity, Selective, and Orally Bioavailable h5-HT2A Receptor Antagonists,”J. Med. Chem., 44: 1603-1614 (2001).
Russell et al., “3-[3-(Piperidin-1-yl)propyl]indoles as Highly Selective h5-HT1D Receptor Agonists,”J. Med. Chem., 42: 4981-5001 (1999).
Speeter et al., “The Action of Oxalyl Chloride on Indoles: A New Approach to Tryptamines,”J. Am. Chem. Soc., 76: 6208-6210 (1954).
Sternfeld et al., “Synthesis and Serotonergic Activity of 3-[2-(Pyrrolidin-1-yl)ethyl]indoles: Potent Agonists for the h5-HT1D Receptor with High Selectivity over the h5-HT1B Receptor,”J. Med. Chem., 42: 677-690 (1999).
van Niel et al., “Fluorination of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(Piperazin-1-yl)propyl)indoles Gives Selective Human 5-HT1D Receptor Ligands with Improved Pharmacokinetic Profiles,”J. Med. Chem., 42: 2087-2104 (1999).
Wiedenau et al., “Facile Synthesis of 2-Benzylindoles,”Synthetic Communications, 27: 2033-2039 (1997).
Wolfe et al., “Simple, Efficient Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, Bromides, and Triflates,”J. Org. Chem., 65: 1158-1174 (2000).
Suh et al. “Novel Potent Antagonists of Transient Receptor Potential Channel, Vanilloid Subfamily Member 1: Structure-Activity Relationship of 1,3,-Diarylalkyl Thioureas Possessing New Vanilloid Equivalents,”J. Med. Chem. 48:5823-5836 (2005).

Affiliated with

Also associated with

Rating

Substituted indole compounds having NOS inhibitory activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted indole compounds having NOS inhibitory activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted indole compounds having NOS inhibitory activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2796105